De Roock, W, Claes, B, Bernasconi, D, De Schutter, J, Biesmans, B, Fountzilas, G, Kalogeras, K T, Kotoula, V, Papamichael, D, Laurent-Puig, P, Penault-Llorca, F, Rougier, P, Vincenzi, B, Santini, D, Tonini, G, Cappuzzo, F, Frattini, M, Molinari, F, Saletti, P, De Dosso, S, Martini, M, Bardelli, A, Siena, S, Sartore-Bianchi, A, Tabernero, J, Macarulla, T, Di Fiore, F, Gangloff, A O, Ciardiello, F, Pfeiffer, P, Qvortrup, C, Hansen, T P, Van Cutsem, E, Piessevaux, H, Lambrechts, D, Delorenzi, M & Tejpar, S 2010, ' Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis ', Lancet Oncology, vol. 11, no. 8, pp. 753-62 . https://doi.org/10.1016/S1470-2045(10)70130-3